{"nctId":"NCT00761631","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years","startDateStruct":{"date":"2008-12"},"conditions":["Healthy Subjects"],"count":1200,"armGroups":[{"label":"Single","type":"EXPERIMENTAL","interventionNames":["Biological: 13 valent pneumococcal conjugate vaccine"]}],"interventions":[{"name":"13 valent pneumococcal conjugate vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects \\>15months to \\<18years in good health, available for entire study period and reachable by phone, parents/legal guardian able and willing to complete all study procedures, written documentation from health professional showing prior vaccination with Prevnar (except for group 4).\n\nGroup 4 only:\n\n* Negative urine pregnancy test for female subjects who are menstruating.\n\nExclusion Criteria:\n\n* Previous reaction or contra-indication to pneumococcal vaccine or vaccine related component , bleeding diathesis, received blood transfusion or blood related products, immune deficiency,congenital malformation.\n\nGroup 4 only:\n\n* Previous vaccination with Prevnar or any other pneumococcal vaccine.\n* Pregnant or breastfeeding adolescent females.","healthyVolunteers":true,"sex":"ALL","minimumAge":"15 Months","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to (â‰¥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After Vaccination in Group 1 and 2","description":"Percentage of participants achieving world health organization (WHO) predefined antibody threshold \\>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on observed proportion of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Measured 1 Month After Vaccination in Group 3","description":"Antibody GMC for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for after dose 1 blood draw.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.18","spread":null}]}]}]},{"type":"PRIMARY","title":"Comparison of Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Measured 1 Month After 13vPnC Vaccination in Group 3 Relative to Posttoddler Responses in Study 6096A1-3005 (NCT00444457)","description":"Comparison of IgG concentrations 1 month after 13vPnC vaccination in group 3 of study 6096A1-3011 (NCT00761631) to posttoddler responses in 7-valent pneumococcal conjugate vaccine (7vPnC) group for 7 common serotypes and in combined 13vPnC groups for 6 additional serotypes of study 6096A1-3005 (NCT00444457) is not reported here because analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in study and described in Participant Flow and Baseline Characteristics modules.","classes":[]},{"type":"PRIMARY","title":"Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination in Group 3 and 4","description":"Serotype-specific OPA GMTs for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for after dose 1 blood draw.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6912","spread":null},{"groupId":"OG001","value":"4629","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14224","spread":null},{"groupId":"OG001","value":"14996","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4485","spread":null},{"groupId":"OG001","value":"4733","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6894","spread":null},{"groupId":"OG001","value":"4759","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6263","spread":null},{"groupId":"OG001","value":"8815","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2280","spread":null},{"groupId":"OG001","value":"1559","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3808","spread":null},{"groupId":"OG001","value":"3245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"319","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"491","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9928","spread":null},{"groupId":"OG001","value":"7514","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6584","spread":null},{"groupId":"OG001","value":"10334","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1276","spread":null},{"groupId":"OG001","value":"1180","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Prespecified Local Reactions Within 7 Days of Dose 1","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"61.9","spread":null},{"groupId":"OG002","value":"45.3","spread":null},{"groupId":"OG003","value":"62.7","spread":null},{"groupId":"OG004","value":"86.8","spread":null},{"groupId":"OG005","value":"89.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"10.6","spread":null},{"groupId":"OG002","value":"5.3","spread":null},{"groupId":"OG003","value":"13.0","spread":null},{"groupId":"OG004","value":"19.5","spread":null},{"groupId":"OG005","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"17.6","spread":null},{"groupId":"OG003","value":"20.0","spread":null},{"groupId":"OG004","value":"37.6","spread":null},{"groupId":"OG005","value":"36.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"20.3","spread":null},{"groupId":"OG002","value":"14.2","spread":null},{"groupId":"OG003","value":"13.5","spread":null},{"groupId":"OG004","value":"21.8","spread":null},{"groupId":"OG005","value":"22.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"7.4","spread":null},{"groupId":"OG003","value":"11.2","spread":null},{"groupId":"OG004","value":"21.9","spread":null},{"groupId":"OG005","value":"21.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"1.1","spread":null},{"groupId":"OG004","value":"3.3","spread":null},{"groupId":"OG005","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"34.9","spread":null},{"groupId":"OG002","value":"18.9","spread":null},{"groupId":"OG003","value":"36.3","spread":null},{"groupId":"OG004","value":"42.9","spread":null},{"groupId":"OG005","value":"30.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"31.5","spread":null},{"groupId":"OG002","value":"16.8","spread":null},{"groupId":"OG003","value":"31.1","spread":null},{"groupId":"OG004","value":"27.9","spread":null},{"groupId":"OG005","value":"21.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"9.9","spread":null},{"groupId":"OG002","value":"5.9","spread":null},{"groupId":"OG003","value":"14.6","spread":null},{"groupId":"OG004","value":"22.0","spread":null},{"groupId":"OG005","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.8","spread":null},{"groupId":"OG003","value":"1.1","spread":null},{"groupId":"OG004","value":"3.3","spread":null},{"groupId":"OG005","value":"1.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Prespecified Local Reactions Within 7 Days of Dose 2","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":null},{"groupId":"OG001","value":"55.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Prespecified Systemic Events Within 7 Days of Dose 1","description":"Systemic events (any fever \\>=38 degrees \\[deg\\] Celsius \\[C\\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"17.5","spread":null},{"groupId":"OG003","value":"14.4","spread":null},{"groupId":"OG004","value":"4.2","spread":null},{"groupId":"OG005","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"4.6","spread":null},{"groupId":"OG003","value":"3.4","spread":null},{"groupId":"OG004","value":"2.4","spread":null},{"groupId":"OG005","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"1.1","spread":null},{"groupId":"OG004","value":"0.5","spread":null},{"groupId":"OG005","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":null},{"groupId":"OG001","value":"24.8","spread":null},{"groupId":"OG002","value":"39.7","spread":null},{"groupId":"OG003","value":"34.0","spread":null},{"groupId":"OG004","value":"22.9","spread":null},{"groupId":"OG005","value":"22.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"72.4","spread":null},{"groupId":"OG003","value":"52.0","spread":null},{"groupId":"OG004","value":"31.2","spread":null},{"groupId":"OG005","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"15.9","spread":null},{"groupId":"OG002","value":"37.0","spread":null},{"groupId":"OG003","value":"23.7","spread":null},{"groupId":"OG004","value":"21.2","spread":null},{"groupId":"OG005","value":"26.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"14.0","spread":null},{"groupId":"OG002","value":"32.1","spread":null},{"groupId":"OG003","value":"18.7","spread":null},{"groupId":"OG004","value":"5.7","spread":null},{"groupId":"OG005","value":"18.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"1.5","spread":null},{"groupId":"OG003","value":"4.5","spread":null},{"groupId":"OG004","value":"1.9","spread":null},{"groupId":"OG005","value":"1.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Prespecified Systemic Events Within 7 Days of Dose 2","description":"Systemic events (any fever \\>=38 deg C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may have been represented in more than 1 category. Percentage of participants = number of participants reporting specified systemic event divided by number of participants reporting yes for at least 1 day or no for all days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"26.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":124},"commonTop":["Tenderness (any)","Irritability","Redness (any)","Decreased appetite","Swelling (any)"]}}}